- Home
- NYT vs HALO Comparison
NYT vs HALO Comparison
Compare NYT & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYT
- HALO
- Stock Information
- Founded
- NYT 1851
- HALO 1998
- Country
- NYT United States
- HALO United States
- Employees
- NYT N/A
- HALO N/A
- Industry
- NYT Newspapers/Magazines
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NYT Consumer Discretionary
- HALO Health Care
- Exchange
- NYT Nasdaq
- HALO Nasdaq
- Market Cap
- NYT 9.3B
- HALO 7.6B
- IPO Year
- NYT N/A
- HALO N/A
- Fundamental
- Price
- NYT $59.85
- HALO $73.15
- Analyst Decision
- NYT Buy
- HALO Buy
- Analyst Count
- NYT 6
- HALO 8
- Target Price
- NYT $60.33
- HALO $70.25
- AVG Volume (30 Days)
- NYT 2.1M
- HALO 2.2M
- Earning Date
- NYT 08-06-2025
- HALO 08-05-2025
- Dividend Yield
- NYT 1.21%
- HALO N/A
- EPS Growth
- NYT 19.25
- HALO 68.93
- EPS
- NYT 1.93
- HALO 4.37
- Revenue
- NYT $2,661,490,000.00
- HALO $1,178,672,000.00
- Revenue This Year
- NYT $9.93
- HALO $32.57
- Revenue Next Year
- NYT $6.51
- HALO $23.25
- P/E Ratio
- NYT $30.96
- HALO $16.77
- Revenue Growth
- NYT 7.88
- HALO 34.97
- 52 Week Low
- NYT $44.83
- HALO $42.01
- 52 Week High
- NYT $62.24
- HALO $74.07
- Technical
- Relative Strength Index (RSI)
- NYT 61.14
- HALO 85.51
- Support Level
- NYT $59.32
- HALO $72.07
- Resistance Level
- NYT $60.30
- HALO $74.07
- Average True Range (ATR)
- NYT 0.95
- HALO 1.41
- MACD
- NYT -0.06
- HALO 0.30
- Stochastic Oscillator
- NYT 68.60
- HALO 91.92
About NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.